Evidence map›Paper›PMID 39319207›Full record

ArticleBeilstein journal of nanotechnology2024

AI-assisted models to predict chemotherapy drugs modified with C

Jonathan-Siu-Loong Robles-Hernández, Dora Iliana Medina, Katerin Aguirre-Hurtado, Marlene Bosquez, Roberto Salcedo, Alan Miralrio

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Beilstein journal of nanotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Raman Spectroscopy of Fullerenes: From CMolecules (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jonathan-Siu-Loong Robles-HernándezTecnologico de Monterrey, Escuela de Ingeniería y Ciencias, Ave. Eugenio Garza Sada 2501, Monterrey 64849, Mexico.ORCID https://orcid.org/0009-0004-8982-0650
Dora Iliana MedinaTecnologico de Monterrey, Institute of Advanced Materials for Sustainable Manufacturing, Monterrey 64849, Mexico.ORCID https://orcid.org/0000-0001-5325-0079
Katerin Aguirre-HurtadoInstituto de Investigaciones en Materiales, Universidad Nacional Autónoma de México, Circuito exterior s/n, Ciudad Universitaria, Coyoacán, 04510, Ciudad de México, Mexico.ORCID https://orcid.org/0009-0000-5084-8008
Marlene BosquezInstituto de Investigaciones en Materiales, Universidad Nacional Autónoma de México, Circuito exterior s/n, Ciudad Universitaria, Coyoacán, 04510, Ciudad de México, Mexico.ORCID https://orcid.org/0009-0008-1268-1153
Roberto SalcedoInstituto de Investigaciones en Materiales, Universidad Nacional Autónoma de México, Circuito exterior s/n, Ciudad Universitaria, Coyoacán, 04510, Ciudad de México, Mexico.ORCID https://orcid.org/0000-0003-1909-7757
Alan MiralrioTecnologico de Monterrey, Escuela de Ingeniería y Ciencias, Ave. Eugenio Garza Sada 2501, Monterrey 64849, Mexico.ORCID https://orcid.org/0000-0002-7992-3718

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Employing quantitative structure-activity relationship (QSAR)/ quantitative structure-property relationship (QSPR) models, this study explores the application of fullerene derivatives as nanocarriers for breast cancer chemotherapy drugs. Isolated drugs and two drug-fullerene complexes (i.e., drug-pristine C

Indexed as

breast cancerCXCR7drug nanocarriersQSAR

Identifiers

PMID39319207
PMCPMC11420546

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.